381 related articles for article (PubMed ID: 22494466)
41. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
Olanow CW
Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
[TBL] [Abstract][Full Text] [Related]
42. Parkinson's disease: drug therapy.
Oertel WH; Quinn NP
Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
[TBL] [Abstract][Full Text] [Related]
43. New and emerging strategies for improving levodopa treatment.
Tolosa ES; Valldeoriola F; Martí MJ
Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259
[TBL] [Abstract][Full Text] [Related]
44. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
Bhidayasiri R; Ling H
J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
[TBL] [Abstract][Full Text] [Related]
45. Early pharmacologic treatment in Parkinson's disease.
Hauser RA
Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870
[TBL] [Abstract][Full Text] [Related]
46. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S
Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536
[TBL] [Abstract][Full Text] [Related]
47. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
Piccoli F; Riuggeri RM
J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
[TBL] [Abstract][Full Text] [Related]
48. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
Gottwald MD
Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
[TBL] [Abstract][Full Text] [Related]
49. Treatment Strategies in Early Parkinson's Disease.
Marsili L; Marconi R; Colosimo C
Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
[TBL] [Abstract][Full Text] [Related]
50. Levodopa: past, present, and future.
Hauser RA
Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
[TBL] [Abstract][Full Text] [Related]
51. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
52. Search for safer and potent natural inhibitors of Parkinson's disease.
Khan ST; Ahmed S; Gul S; Khan A; Al-Harrasi A
Neurochem Int; 2021 Oct; 149():105135. PubMed ID: 34271080
[TBL] [Abstract][Full Text] [Related]
53. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
54. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
55. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.
Haddad F; Sawalha M; Khawaja Y; Najjar A; Karaman R
Molecules; 2017 Dec; 23(1):. PubMed ID: 29295587
[No Abstract] [Full Text] [Related]
56. Novel pharmacological targets for the treatment of Parkinson's disease.
Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
[TBL] [Abstract][Full Text] [Related]
57. The evolution of pharmacological treatment for Parkinson's disease.
Almeida QJ; Hyson HC
Recent Pat CNS Drug Discov; 2008 Jan; 3(1):50-4. PubMed ID: 18221241
[TBL] [Abstract][Full Text] [Related]
58. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
Laurencin C; Danaila T; Broussolle E; Thobois S
Rev Neurol (Paris); 2016; 172(8-9):512-523. PubMed ID: 27476416
[TBL] [Abstract][Full Text] [Related]
59. Dopamine receptor agonists for Parkinson's disease.
Blandini F; Armentero MT
Expert Opin Investig Drugs; 2014 Mar; 23(3):387-410. PubMed ID: 24313341
[TBL] [Abstract][Full Text] [Related]
60. [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Woitalla D; Krüger R; Lorenzl S; Müller T; Oelwein G; Storch A; Wolz M; Wüllner U
Fortschr Neurol Psychiatr; 2020 Sep; 88(9):620-633. PubMed ID: 32588409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
